{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Brunner E"],"funding":["FDA HHS","Food and Drug Administration"],"pagination":["2814-2859"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12463801"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(12)"],"pubmed_abstract":["<h4>Description</h4>The American Society of Addiction Medicine (ASAM) has partnered with nine other medical societies and professional associations representing a wide range of clinical settings and patient populations to provide guidance on evidence-based strategies for tapering benzodiazepine (BZD) medication across a variety of settings.<h4>Methods</h4>The guideline was developed following modified GRADE methodology and clinical consensus process. The process included a systematic literature review as well as several targeted supplemental searches. The clinical practice guideline was revised based on external stakeholder review.<h4>Recommendations</h4>Key takeaways included the following: Clinicians should engage in ongoing risk-benefit assessment of BZD use/tapering, clinicians should "],"journal":["Journal of general internal medicine"],"pubmed_title":["Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits."],"pmcid":["PMC12463801"],"funding_grant_id":["U01FD007804"],"pubmed_authors":["Sanders AE","Brunner E","Klein T","ASAM Staff and Contractors","VandenBerg A","Snodgrass B","Devoto A","Norrington J","Framnes-DeBoer S","Maust D","Chen CA","Mecca M","Rajneesh KF","Wright T","Mazer-Amirshahi M","Boyle M","Clinical Guideline Committee (CGC) Members","Ogbonna C","Kleykamp B","Lindsay D","Roll E","Najera D"],"additional_accession":[]},"is_claimable":false,"name":"Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits.","description":"<h4>Description</h4>The American Society of Addiction Medicine (ASAM) has partnered with nine other medical societies and professional associations representing a wide range of clinical settings and patient populations to provide guidance on evidence-based strategies for tapering benzodiazepine (BZD) medication across a variety of settings.<h4>Methods</h4>The guideline was developed following modified GRADE methodology and clinical consensus process. The process included a systematic literature review as well as several targeted supplemental searches. The clinical practice guideline was revised based on external stakeholder review.<h4>Recommendations</h4>Key takeaways included the following: Clinicians should engage in ongoing risk-benefit assessment of BZD use/tapering, clinicians should ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-03T20:23:19.526Z","creation":"2026-05-01T03:10:09.142Z"},"accession":"S-EPMC12463801","cross_references":{"pubmed":["40526204"],"doi":["10.1007/s11606-025-09499-2"]}}